Is Xolair really "superior" to OIT?

I recently attended the AAAAI 2025 conference, where I was invited to speak on the ages and stages of school-aged children with food allergies. The audience of the session was fantastic, and I had a blast discussing such an important topic.

Unsurprisingly, throughout the conference, Xolair was the topic du jour. Sparked by the bold headline "Omalizumab is superior to Oral Immunotherapy in Multi-Food Allergy Study," my colleagues and I had frank discussions about our thoughts on the topic including the OUtMATCH study itself.

For my musings on this important topic, check out two articles I've written:

• Article on Doximity

• Article on Food Allergy Peds Hub

In case you were wondering how they compared OIT to Xolair...

Below is a comparison of the OIT protocol used in the OUtMATCH study compared to the Palforzia OIT protocol, which is one of if not the most well studied, commonly used OIT protocols in existence:

As you can see, the OIT protocol used in OUtMATCH was much more aggressive than the Palforzia OIT protocol. For example, when an OUtMATCH subject was reaching 1,000mg of allergenic protein, a Palforzia patient would just be reaching 200mg. Because the OUtMATCH protocol was this aggressive, I am not surprised there were so very many adverse reactions in the OIT group of the OUtMATCH trial.

Check out the articles linked above, and talk with your allergist about Xolair and OIT.

Questions? I hope you'll reach out!